Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

被引：7

作者：

Kotecki, N. ^{[1
]}

Champiat, S. ^{[2
]}

Delord, J-P. ^{[3
]}

Vinceneux, A. ^{[4
]}

Jungels, C. ^{[1
]}

Marabelle, A. ^{[2
]}

Korakis, I. ^{[3
]}

Wojciekowski, S. ^{[5
]}

Block, E. ^{[6
]}

Clarke, N. ^{[7
]}

Fromond, C. ^{[8
]}

Poirier, N. ^{[9
]}

Costantini, D. ^{[10
]}

Vasseur, B. ^{[11
]}

Cassier, P. A. ^{[4
]}

机构：

[1] Inst Jules Bordet, Med Oncol, Brussels, Belgium

[2] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France

[3] Inst Claudius Regaud, Dept Med Oncol, IUCT Oncopole, Toulouse, France

[4] Ctr Leon Berard, Med Oncol, Lyon, France

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Stat, Biberach, Germany

[6] Boehringer Ingelheim Pharmaceut Inc, Clin Dev, Ridgefield, CT USA

[7] Boehringer Ingelheim Pharma GmBH & Co KG, Translat Med & Clin Pharmacol, Ingelheim, Germany

[8] OSE Immunotherapeut, Preclin Dev & Translat Med, Paris, France

[9] OSE Immunotherapeut, Res Dept, Nantes, France

[10] OSE Immunotherapeut, Early Dev, Paris, France

[11] OSE Immunotherapeut, Immunooncol, Paris, France

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1367

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

983P

引用

页码：S841 / S842

页数：2

共 50 条

[1] A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours
Marabelle, A.
Cassier, P.
Delord, J-P.
Jungles, C.
Champiat, S.
Vinceneux, A.
Korakis, I.
Huhn, R.
Poirier, N.
Vasseur, B.
Kotecki, N.
ANNALS OF ONCOLOGY, 2019, 30
[2] A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours
Delord, Jean-Pierre
Kotecki, Nuria
Marabelle, Aurelien
Vinceneux, Armelle
Korakis, Iphigenie
Jungels, Christiane
Champiat, Stephane
Huhn, Richard D.
Poirier, Nicolas
Costantini, Dominique
Vasseur, Berangere
Cassier, Philippe A.
BLOOD, 2019, 134
[3] A phase 1 study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as stand-alone and in combination with BI 754091, a PD-1 inhibitor, in patients with advanced solid tumours
Kotecki, Nuria
Cassier, Philippe
Delord, Jean-Pierre
Champiat, Stephane
Jungels, Christiane
Vinceneux, Armelle
Korakis, Iphigenie
Huhn, Richard
Poirier, Nicolas
Costantini, Dominique
Vasseur, Berangere
Marabelle, Aurelien
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[4] Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.
Johnson, Melissa Lynne
Patel, Manish R.
Siu, Lillian L.
Kozloff, Mark
Aljumaily, Raid
Vaishampayan, Ulka N.
Elgadi, Mabrouk M.
Ge, Miaomiao
Duffy, Christine
Graeser, Ralph
Khedkar, Sheetal Vinay
Jones, Suzanne Fields
Burris, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[5] A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors
Johnson, Melissa
Patel, Manish
Siu, Lillian
Aljumaily, Raid
Kozloff, Mark
Vaishampayan, Ulka
Elgadi, Mabrouk
Ge, Miaomiao
Duffy, Christine
Graeser, Ralph
Buschke, Susanne
Khedkar, Sheetal
Jones, Suzanne F.
Burrisiii, Howard A.
ANNALS OF ONCOLOGY, 2018, 29
[6] Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
Champiat, Stephane
Cassier, Philippe A.
Kotecki, Nuria
Korakis, Iphigenie
Vinceneux, Armelle
Jungels, Christiane
Blatchford, Jon
Elgadi, Mabrouk M.
Clarke, Nicole
Fromond, Claudia
Poirier, Nicolas
Vasseur, Berangere
Marabelle, Aurelien
Delord, Jean-Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors
Champiat, Stephane
Cassier, Philippe A.
Kotecki, Nuria
Gomez-Roca, Carlos
Korakis, Iphigenie
Kaissa, Ouali
Italiano, Antoine
Elgadi, Mabrouk M.
Vandewalle, Thomas
Girault, Isabelle
Guen, Nina Salabert-Le
O'Brien, Donogh
Poirier, Nicolas
Vasseur, Berangere
Costantini, Dominique
Fromond, Claudia
Bono, Francoise
Delord, Jean-Pierre
CANCER RESEARCH, 2023, 83 (07)
[8] Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC)
Meyer, Tim
Ledin, Evgeny
Kim, Dong-Wan
Ghiringhelli, Francois
Serwatowski, Piotr
Voskoboynik, Mark
Landsteiner, Harald Timotheus
Chen, Victoria
Jayadeva, Girish
Macarulla, Teresa
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[9] Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors
Yamamoto, Noboru
Koyama, Takafumi
Shimizu, Toshio
Todaka, Akiko
Kawakami, Takeshi
Erzen, Damijan
Sarashina, Akiko
Li, Bin
Hou, Jianrui
Yamazaki, Kentaro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (06) : 469 - 480
[10] A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours
Schoeffski, P.
Awada, A.
Dumez, H.
Gil, T.
Bartholomeus, S.
Selleslach, J.
Taton, M.
Fritsch, H.
Peter, N.
Munzert, G.
EJC SUPPLEMENTS, 2008, 6 (12): : 14 - 15

← 1 2 3 4 5 →